However, in an in vivo model, the inhibition of HSP90 by ganetespib significantly decreased tumor growth and vascularization through a mechanism related to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, also known as Apo2L), which was found to be a potent activator of apoptosis [82,83]. The gene discussed is HSP90AA1; the disease is neoplasm.